Differentiated thyroid cancer (DTC): therapeutic updates and optimizing treatment

Details

The incidence of differentiated thyroid cancer (DTC) is on the rise over the past 10 years and roughly 57,000 new cases were reported in 2017 alone.

After completing Differentiated thyroid cancer (DTC): therapeutic updates and optimizing treatment physicians will better be able to: 

• Recognize factors affecting the diagnosis, staging, and prognosis of patients with DTC.
• Identify present and emerging pharmacotherapeutic treatments for the management of unresectable DTC and apply them to patient cases using evidence-based medicine
• Describe how to manage challenges that arise during treatment with approved and investigational medicines for DTC, including adverse effect management, and apply** that knowledge to a patient case
• Describe the challenges associated with DTC treatment, focusing specifically on the risks (e.g., adverse drug reactions, drug interactions, etc.) of the agents used to treat the disease, and apply that information in a patient case

Target Audience: medical oncologists, endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with DTC.